Orthologies: 0 | Equivalencies: 0 | Classes: 0 | Children: 0 | Explore

Appears in Networks 1

In-Edges 4

act(a(CHEBI:tacrine)) negativeCorrelation g(HGNC:APOE) View Subject | View Object

The APOE-epsilon4 gene-dose effect was also found to correlate with the loss of nAChR binding sites in patients with AD, as well as a reduced respon- siveness to the therapeutic AChE inhibitor tacrine (Poirier et al., 1995). Within an AD cohort, APOE-epsilon4 dose dependently correlates with higher losses of ChAT but not with losses in alpha4beta2 nAChRs (Lai et al., 2006). PubMed:19293145

act(p(HGNCGENEFAMILY:"Cholinergic receptors nicotinic subunits")) association g(HGNC:APOE) View Subject | View Object

The APOE-epsilon4 gene-dose effect was also found to correlate with the loss of nAChR binding sites in patients with AD, as well as a reduced respon- siveness to the therapeutic AChE inhibitor tacrine (Poirier et al., 1995). Within an AD cohort, APOE-epsilon4 dose dependently correlates with higher losses of ChAT but not with losses in alpha4beta2 nAChRs (Lai et al., 2006). PubMed:19293145

p(HGNC:CHAT) negativeCorrelation g(HGNC:APOE) View Subject | View Object

The APOE-epsilon4 gene-dose effect was also found to correlate with the loss of nAChR binding sites in patients with AD, as well as a reduced respon- siveness to the therapeutic AChE inhibitor tacrine (Poirier et al., 1995). Within an AD cohort, APOE-epsilon4 dose dependently correlates with higher losses of ChAT but not with losses in alpha4beta2 nAChRs (Lai et al., 2006). PubMed:19293145

path(MESH:"Alzheimer Disease") positiveCorrelation g(HGNC:APOE) View Subject | View Object

The apolipoprotein E type 4 allele (APOE-epsilon4) encodes the APOE lipoprotein, which through its lipid transport function plays a role in lipid metabolism. APOE-epsilon4 has been found to be a major risk factor for late familial or sporadic AD, with a strong gene-dosage effect such that the number of APOE-epsilon4 alleles correlated positively with the risk of developing AD and the age of onset (Corder et al., 1993). PubMed:19293145

Out-Edges 6

g(HGNC:APOE) increases p(HGNC:APOE) View Subject | View Object

The apolipoprotein E type 4 allele (APOE-epsilon4) encodes the APOE lipoprotein, which through its lipid transport function plays a role in lipid metabolism. APOE-epsilon4 has been found to be a major risk factor for late familial or sporadic AD, with a strong gene-dosage effect such that the number of APOE-epsilon4 alleles correlated positively with the risk of developing AD and the age of onset (Corder et al., 1993). PubMed:19293145

g(HGNC:APOE) positiveCorrelation path(MESH:"Alzheimer Disease") View Subject | View Object

The apolipoprotein E type 4 allele (APOE-epsilon4) encodes the APOE lipoprotein, which through its lipid transport function plays a role in lipid metabolism. APOE-epsilon4 has been found to be a major risk factor for late familial or sporadic AD, with a strong gene-dosage effect such that the number of APOE-epsilon4 alleles correlated positively with the risk of developing AD and the age of onset (Corder et al., 1993). PubMed:19293145

g(HGNC:APOE) association act(p(HGNCGENEFAMILY:"Cholinergic receptors nicotinic subunits")) View Subject | View Object

The APOE-epsilon4 gene-dose effect was also found to correlate with the loss of nAChR binding sites in patients with AD, as well as a reduced respon- siveness to the therapeutic AChE inhibitor tacrine (Poirier et al., 1995). Within an AD cohort, APOE-epsilon4 dose dependently correlates with higher losses of ChAT but not with losses in alpha4beta2 nAChRs (Lai et al., 2006). PubMed:19293145

g(HGNC:APOE) negativeCorrelation p(HGNC:CHAT) View Subject | View Object

The APOE-epsilon4 gene-dose effect was also found to correlate with the loss of nAChR binding sites in patients with AD, as well as a reduced respon- siveness to the therapeutic AChE inhibitor tacrine (Poirier et al., 1995). Within an AD cohort, APOE-epsilon4 dose dependently correlates with higher losses of ChAT but not with losses in alpha4beta2 nAChRs (Lai et al., 2006). PubMed:19293145

g(HGNC:APOE) negativeCorrelation act(a(CHEBI:tacrine)) View Subject | View Object

The APOE-epsilon4 gene-dose effect was also found to correlate with the loss of nAChR binding sites in patients with AD, as well as a reduced respon- siveness to the therapeutic AChE inhibitor tacrine (Poirier et al., 1995). Within an AD cohort, APOE-epsilon4 dose dependently correlates with higher losses of ChAT but not with losses in alpha4beta2 nAChRs (Lai et al., 2006). PubMed:19293145

g(HGNC:APOE) causesNoChange complex(p(HGNC:CHRNA4), p(HGNC:CHRNB2)) View Subject | View Object

The APOE-epsilon4 gene-dose effect was also found to correlate with the loss of nAChR binding sites in patients with AD, as well as a reduced respon- siveness to the therapeutic AChE inhibitor tacrine (Poirier et al., 1995). Within an AD cohort, APOE-epsilon4 dose dependently correlates with higher losses of ChAT but not with losses in alpha4beta2 nAChRs (Lai et al., 2006). PubMed:19293145

About

BEL Commons is developed and maintained in an academic capacity by Charles Tapley Hoyt and Daniel Domingo-Fernández at the Fraunhofer SCAI Department of Bioinformatics with support from the IMI project, AETIONOMY. It is built on top of PyBEL, an open source project. Please feel free to contact us here to give us feedback or report any issues. Also, see our Publishing Notes and Data Protection information.

If you find BEL Commons useful in your work, please consider citing: Hoyt, C. T., Domingo-Fernández, D., & Hofmann-Apitius, M. (2018). BEL Commons: an environment for exploration and analysis of networks encoded in Biological Expression Language. Database, 2018(3), 1–11.